Loading stock data…
LB Pharmaceuticals Inc (LBRX)
$49.39+0.05 (+0.10%)
Market ClosedLast close Sep 8
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LB Pharmaceuticals Inc in the Healthcare sector is trading at $49.39 with a market capitalization of $802M. Wall Street consensus targets $53.38 (8 analysts), implying a +8.1% move over the next 12 months. The stock is currently near its 52-week high of $50.16, remaining 71.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +8.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.10M↓ | -$13.87M↓ | -$5.25M↓ | -$4.86M↑ | -$6.43M |
| Net Income | -$19.05M↓ | -$11.47M↓ | -$3.56M↑ | -$4.87M↑ | -$5.31M |
Peer Comparison
JNJUNHPFE
Fundamentals
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$801.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.29%
Volume
Today's trading volume
300,803
Recent News
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
LB Pharmaceuticals (LBRX) has drawn fresh investor attention after appointing Joseph M. Miller as Chief Financial Officer. The announcement coincides with preparations for NOVA-2 trial readouts and a potential LB-102 launch in schizophrenia. Despite a pullback over the last day with a 1-day share price return of down 3.96% to US$47.52, LB Pharmaceuticals has delivered a 66.56% 90-day share price return and a 132.49% year-to-date share price return, which suggests that momentum has been...
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list. TheFly reported on May 28 that Clear Street maintained a Buy rating and a $45 price target for LBRX. The firm stated that […]
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.